Rosuvastatin treatment was associated with a significant reduction in CIAKI compared with the controls ( 2.1 % vs. 4.4 % , P = 0.050 ) in the overall cohort and in patients with MCV ( 1.7 % vs. 4.5 % , P = 0.029 ) , whereas no benefit was observed in patients with HCV ( 3.4 % vs. 3.9 % , P = 0.834 ) .